PPA1 / Inorganic pyrophosphatase · IHC design guide

Design Immunohistochemistry for PPA1

Plan PPA1 staining in paraffin sections using its observed cytoplasmic and nuclear tissue pattern (HPA tissue IHC). The guide covers fixation consistency, antigen retrieval and interpretation of the catalog antibody’s chromogenic IHC protocol (datasheet A07485-1).

Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use

Immunohistochemistry protocol sheet for PPA1 (IHC for PPA1): expected localisation Cytoplasmic and nuclear tissue staining (HPA tissue IHC), antibody A07485-1, validated IHC image, and IHC protocol steps — Printable **PPA1** IHC protocol sheet — expected localisation Cytoplasmic and nuclear tissue staining (HPA tissue IHC), antibody A07485-1, controls and protocol steps. Open the full PPA1 IHC guide →

Navigate to: Protocols Staining pattern Controls Antibodies

PPA1 Immunohistochemistry Experimental Design Guide

Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before staining

	Expected localisation	Cytoplasmic and nuclear tissue staining (HPA tissue IHC)
	Staining pattern	Glandular and epithelial cells stain in cytoplasm and nucleus (HPA tissue IHC)
	Antigen retrieval	Citrate pH 6 HIER, heat-mediated (datasheet A07485-1)
	Positive control ⓘ	Adrenal gland+4 more · see all
	Negative control ⓘ	None in HPA (detected in all 45 tissues); use no-primary + isotype controls

Important caveats

Reasons your staining may differ from the expected pattern.

	Fixation	Keep fixation consistent across sections. (standard IHC practice; not target-specific)
	Caveat	Staining has only medium concordance with RNA data (HPA tissue IHC)
	Regulation	No expression regulator is documented (UniProt)
	Isoform / epitope	No annotated isoforms; the chain spans aa 2–289 (UniProt)

Section 1

Recommended PPA1 IHC & IF Protocols

Compare the catalog antibody's IHC-P protocol (datasheet: A07485-1) with published PPA1 IHC protocols for tumor tissue (PMC5083733) and frontal lobe tissue (PMC13236917).

Recommended immunohistochemistry (IHC-P) protocol parameters
Sample	Paraffin-embedded human intestinal cancer tissue; fixative not specified (datasheet A07485-1)
Fixation	Image fixative and duration unreported (datasheet A07485-1); verify before use.
Sectioning	4–5 µm sections on charged slides (standard)
Deparaffinisation	Xylene, graded ethanol series to water (standard)
Antigen retrieval	Heat retrieval: Citrate pH 6, 20 min (datasheet A07485-1)
Peroxidase block	3% H2O2, 10 min, room temperature (standard)
Blocking	10% goat serum (datasheet A07485-1)
Primary antibody	Rabbit anti-PPA1, 0.5-1μg/ml (datasheet A07485-1)
Primary incubation	Overnight at 4 °C (datasheet A07485-1)
Detection	Streptavidin-biotin complex (SABC), DAB chromogen (datasheet A07485-1)
Counterstain	Hematoxylin, blue, dehydrate and mount (standard)
Expected result	PPA1-positive staining in glandular cells of adrenal gland (HPA tissue IHC: High). HPA tissue profile: Cytoplasmic and nuclear expression in most tissues. No signal in the no-primary control.

💡Decision noteStart with heat-mediated citrate pH 6 retrieval (datasheet: A07485-1); the tumor study used citric acid pH 6.4 at 121°C for 10 min (PMC5083733).

Section 2

What Is the Expected PPA1 Staining Pattern?

PPA1 is cytoplasmic by UniProt annotation and has no transmembrane segment (UniProt Q15181). In tissue IHC, expect cytoplasmic and nuclear staining in many cell types, including strong staining in colon glandular cells and bronchial respiratory epithelial cells (HPA tissue IHC: High). HPA rates the tissue pattern Supported, with medium agreement between staining and RNA data and external verification pending (HPA tissue IHC).

What am I looking at on my slide?
Distinct cytoplasmic staining, with nuclear staining in glandular or respiratory epithelial cells.	This fits the tissue pattern (HPA tissue IHC: cytoplasmic and nuclear expression in most tissues). Compare intensity with a known high-staining cell population on the same run; a clean compartment pattern is more informative than color alone (general IHC practice).
Staining is confined to the cell surface, with little cytoplasmic or nuclear signal.	An exclusively surface pattern is discordant with the reported tissue pattern (HPA tissue IHC) and the absence of a transmembrane segment (UniProt Q15181). Review morphology and detection controls before assigning this signal to PPA1; nuclear staining alone is not a wrong compartment (HPA tissue IHC).
The strongest signal falls in cells outside the expected positive population.	For example, dominant adipocyte staining alongside weak glandular staining reverses the supplied tissue comparison (HPA tissue IHC: Low in adipocytes; High in several glandular populations). Consider antibody cross-reactivity or endogenous detection activity, then check controls (general IHC practice).
Color spreads across stroma, empty spaces, and multiple cell compartments without clear boundaries.	This diffuse pattern is difficult to score as cellular PPA1 staining. Background from detection reagents or inadequate blocking is possible (general IHC practice); it cannot be rescued by the broad tissue-expression profile (UniProt Q15181: ubiquitous; HPA tissue IHC: most tissues).
A known high-staining tissue shows no cellular signal.	Loss of signal in colon glandular cells or bronchial respiratory epithelium is unexpected (HPA tissue IHC: High). Check the staining run and antibody conditions before treating the slide as biologically negative (general IHC practice). HPA supplies no negative reference tissue for this panel (HPA tissue IHC).

💡Expected PPA1 appearanceCall a positive result when glandular or respiratory epithelial cells show clear cytoplasmic, often nuclear, staining with strong signal in listed high-level tissues (HPA tissue IHC); isolated surface color or diffuse acellular deposit is suspicious (UniProt Q15181 topology; general IHC practice).

How each factor affects the staining
Tissue and cell population	PPA1 is broadly expressed (UniProt Q15181: ubiquitous; HPA tissue IHC: low tissue specificity). Use the named cell population when judging intensity: colon glandular and bronchial respiratory epithelial cells are High, while cardiomyocytes, myocytes, adipocytes, and marrow hematopoietic cells are Low (HPA tissue IHC). Low does not mean absent.
Compartment in tissue sections	Tissue IHC reports cytoplasmic and nuclear staining in most tissues (HPA tissue IHC), whereas UniProt annotates cytoplasm (UniProt Q15181). Treat the observed nuclear component as part of the HPA tissue pattern, while keeping the difference between experimental staining and the UniProt annotation explicit.
IHC antibody evidence	Two listed rabbit polyclonal antibodies have Supported IHC status (HPA antibodies: HPA019878, HPA020096). The overall tissue profile is also Supported, with medium staining–RNA agreement and external verification pending (HPA tissue IHC). These ratings support pattern comparison but do not make every unexpected signal specific.
IF/ICC expectation?	HPA reports supported vesicular localization in ICC-IF, with images from A-431, U-251MG, and U2OS (HPA subcellular). This is a cell-imaging observation; do not substitute it for the cytoplasmic and nuclear tissue-IHC pattern (HPA tissue IHC). This page provides no IF/ICC protocol option.
Assay conditions and interpretation	The supplied sources give no PPA1-specific fixation or antigen-retrieval effect. If a run fails, review retrieval, antibody dilution, blocking, detection, and counterstain as general IHC variables (general IHC practice), without claiming that any one condition changes PPA1 sensitivity.

Why is my staining missing, weak or wrong?
Situation	Likely cause	Next action
No signal in a high-level control population.	A staining-run problem is possible when colon glandular or bronchial respiratory epithelial cells are blank (HPA tissue IHC: High).	Check that the IHC-validated antibody, retrieval, dilution, detection reagents, and counterstain were used as intended; verify controls before scoring the specimen (general IHC practice).
Only weak staining in muscle, adipose tissue, or marrow.	These listed populations have Low staining (HPA tissue IHC: cardiomyocytes, smooth muscle cells, myocytes, adipocytes, hematopoietic cells).	Compare with a listed High cell population in the same run before changing assay settings; weak signal here alone does not establish assay failure (HPA tissue IHC; general IHC practice).
Prominent edge, stromal, or acellular color obscures cells.	Nonspecific background or detection deposits may obscure compartment scoring (general IHC practice).	Review a no-primary control, blocking, washes, and chromogen development; score only interpretable cellular staining (general IHC practice).
Unexpectedly strong staining in a listed Low population.	Cross-reactivity or endogenous detection activity is possible (general IHC practice); the intensity conflicts with the supplied comparison (HPA tissue IHC: Low).	Inspect morphology and appropriate detection controls, then compare a listed High population and, if available, staining with another IHC-supported antibody (HPA antibodies; general IHC practice).
Signal appears exclusively at the plasma membrane.	That pattern does not match cytoplasmic and nuclear tissue staining (HPA tissue IHC) or a membrane-spanning PPA1 protein (UniProt Q15181: no transmembrane segment).	Check section morphology and background controls, then repeat staining under the established IHC procedure if the compartment remains unclear (general IHC practice).
ICC-IF shows puncta while tissue IHC looks more diffuse.	HPA records supported vesicular ICC-IF localization and cytoplasmic plus nuclear tissue staining (HPA subcellular; HPA tissue IHC).	Interpret each image against its own assay-specific HPA observation; do not use punctate ICC-IF as a required appearance or protocol setting for paraffin IHC (HPA subcellular; HPA tissue IHC).

Source: UniProt Q15181 Human Protein Atlas tissue Human Protein Atlas subcellular

Experiment evidence

IHC & IF images showing PPA1 staining

IHC analysis of PPA1 using anti-PPA1 antibody (A07485-1). PPA1 was detected in paraffin-embedded section of human intestinal cancer tissue. Heat mediated antigen retrieval was performed in citrate buffer (pH6, epitope retrieval solution) for 20 mins. The tissue section was blocked with 10% goat serum. The tissue section was then incubated with 1μg/ml rabbit anti-PPA1 Antibody (A07485-1) overnight at 4°C. Biotinylated goat anti-rabbit IgG was used as secondary antibody and incubated for 30 minutes at 37°C. The tissue section was developed using Strepavidin-Biotin-Complex (SABC)(Catalog # SA1022) with DAB as the chromogen.

A07485-1 · IHCIHC analysis of PPA1 using anti-PPA1 antibody (A07485-1). PPA1 was detected in paraffin-embedded section of human intestinal cancer tissue.

IHC analysis of PPA1 using anti-PPA1 antibody (A07485-1). PPA1 was detected in paraffin-embedded section of mouse brain tissue. Heat mediated antigen retrieval was performed in citrate buffer (pH6, epitope retrieval solution) for 20 mins. The tissue section was blocked with 10% goat serum. The tissue section was then incubated with 1μg/ml rabbit anti-PPA1 Antibody (A07485-1) overnight at 4°C. Biotinylated goat anti-rabbit IgG was used as secondary antibody and incubated for 30 minutes at 37°C. The tissue section was developed using Strepavidin-Biotin-Complex (SABC)(Catalog # SA1022) with DAB as the chromogen.

A07485-1 · IHCIHC analysis of PPA1 using anti-PPA1 antibody (A07485-1). PPA1 was detected in paraffin-embedded section of mouse brain tissue. Heat mediate

HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000180817-PPA1/tissue/cerebral+cortex#imid_5445864

HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000180817-PPA1/tissue/colon#imid_5445798

HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000180817-PPA1/tissue/liver#imid_5445791

HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000180817-PPA1/tissue/kidney#imid_5445808

HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA020096; green = PPA1, blue = nucleus, red = microtubules.

← swipe / scroll for more images →

Real IHC / IF data behind the staining-pattern expectations in this section.

Sample controls for PPA1 IHC & IF

🧪Run adrenal gland first and look for staining in glandular cells (HPA: High in adrenal gland glandular cells). HPA detects PPA1 in all 45 scored tissues, so there is no supported negative tissue; use no-primary and isotype controls, and do not designate any cells on the positive slide as inherently PPA1-negative (HPA: no negative tissue rows; UniProt Q15181: ubiquitous expression).

Positive control tissue: Adrenal gland (Glandular cells, HPA High)

Negative control tissue: None in HPA: PPA1 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead.

ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show PPA1 in A-431, U-251MG, U2OS, with annotated localisation: Vesicles (supported) (HPA subcellular).

Technical controls: Include a no-primary, secondary-only section, a matched nonimmune rabbit IgG control, and a PPA1 knockout sample if available (caption: rabbit anti-PPA1 antibody; standard IHC practice). For chromogenic detection, quench endogenous peroxidase and check for endogenous biotin background, especially with the caption's biotin-based detection system (caption: biotinylated secondary, streptavidin-biotin complex and DAB; standard IHC practice).

⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected SKU's paraffin-section caption does not state a fixative (caption: fixative unreported). Heat retrieval in citrate buffer at pH 6 for 20 minutes is a documented IHC starting point, but its effect in adrenal gland has not been established by the supplied caption (caption: human intestinal cancer section). There is no supplied basis to say frozen sections or IF are easier; HPA reports vesicular ICC-IF localization in A-431, U-251MG and U2OS, while the IHC caption's biotin-based DAB detection calls for background checks (HPA: subcellular ICC-IF; caption: streptavidin-biotin complex and DAB).

HPA tissue IHC evidence for PPA1

Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Supported — Medium consistency between antibody staining and RNA expression data. Pending external verification.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Positive expression · recommended positive controls

Tissue	Cell type	Level	Evidence	Source
Adrenal gland	Glandular cells	High	Protein (IHC)	HPA →
Appendix	Glandular cells	High	Protein (IHC)	HPA →
Breast	Glandular cells	High	Protein (IHC)	HPA →
Bronchus	Respiratory epithelial cells	High	Protein (IHC)	HPA →
Cerebellum	Granular cells - cytoplasm/membrane	High	Protein (IHC)	HPA →

Undetected expression · recommended negative controls

Tissue	Cell type	Level	Evidence	Source
None in HPA: PPA1 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead.

Section 3

Advanced PPA1 IHC Tips

Troubleshoot PPA1 chromogenic IHC in paraffin sections by checking retrieval, staining distribution, controls, and scoring against the supplied evidence.

How should I optimize retrieval when PPA1 staining is weak in paraffin sections?

Use heat-mediated citrate retrieval at pH 6 for PPA1 paraffin sections (datasheet A07485-1). The selected tissue image used 20 minutes of retrieval before staining (caption A07485-1). Start with that condition, then compare heating times on matched sections while keeping antibody concentration, detection, and imaging conditions constant (general IHC practice). If staining remains weak, test an alternative retrieval buffer as a fallback, alongside tissue morphology and background controls (general IHC practice). Interpret any gain cautiously because the documented PPA1 result establishes the citrate condition for this antibody, but does not establish an optimum across tissues (caption A07485-1).

Could fixation explain inconsistent PPA1 staining between paraffin tissue blocks?

PPA1-specific fixation sensitivity is unknown: the selected image identifies paraffin embedding but does not report its fixative (caption A07485-1). Record each block’s fixative and fixation duration, and compare sections with similar processing histories before attributing an intensity difference to PPA1 biology (general IHC practice). If preparing new material, use a consistent fixation procedure and pilot matched blocks rather than assuming that the published staining pattern predicts fixation tolerance (general IHC practice). Keep the documented citrate retrieval at pH 6 for 20 minutes as the starting staining condition while testing fixation as a separate variable (datasheet A07485-1; caption A07485-1).

What PPA1 staining distribution should I expect, and how should I assess nuclear signal?

Evaluate cytoplasmic staining first because PPA1 is annotated in the cytoplasm (UniProt Q15181), while tissue IHC also reports cytoplasmic and nuclear expression in most tissues (HPA tissue IHC). Examine glandular cells in colon as a comparison because high staining is reported there (HPA: High in colon glandular cells). Score nuclear and cytoplasmic DAB separately, using morphology and a counterstain to define cell boundaries (general IHC practice). A nuclear signal is therefore worth documenting, but confirm it across matched sections and controls before treating it as a distinct biological change (HPA tissue IHC; general IHC practice).

Could PPA1 processing or modifications change what this antibody detects in tissue?

PPA1 has no annotated isoforms or transmembrane segment, and its annotated chain spans residues 2–289 (UniProt Q15181). Reported modifications include acetylation at residues 2, 57, and 228, plus phosphorylation at 250 (UniProt Q15181). The supplied evidence does not map this antibody’s epitope, so those modifications cannot be assigned a staining effect from these data (UniProt Q15181; caption A07485-1). If retrieval changes the pattern, compare matched sections and, where an independently mapped antibody is available, examine agreement in cell distribution before proposing epitope masking or a PPA1 variant (general IHC practice).

How can IF help check a PPA1 pattern seen by chromogenic IHC?

Use IF as a complementary localisation check, keeping the paraffin-section DAB result as the IHC reference (caption A07485-1). Multiplex PPA1 with a marker for the expected cell population, such as glandular cells in a tissue where they show high PPA1 staining, and choose a far-red fluorophore after checking tissue autofluorescence (HPA: High in colon glandular cells; general IF practice). Because PPA1 lacks a transmembrane segment and is annotated in the cytoplasm, permeabilise sufficiently to expose its intracellular epitope without assuming a membrane-facing epitope (UniProt Q15181; general IF practice). Assess possible puncta alongside diffuse signal, since vesicular localisation is reported in cell imaging (HPA subcellular).

How do I reduce diffuse brown signal without suppressing PPA1 staining?

First compare the stained section with a no-primary control and inspect whether brown signal follows cell outlines or pools at tissue edges (general IHC practice). The selected PPA1 image used 10% goat serum, a biotinylated secondary antibody, a streptavidin–biotin complex, and DAB (caption A07485-1). Apply an endogenous peroxidase block and assess endogenous biotin where relevant to that detection scheme; these are general chromogenic IHC controls, not PPA1-specific requirements (general IHC practice). If background persists, titrate primary antibody around the documented 1 µg/ml condition while holding retrieval and DAB development constant, then retain the setting that preserves interpretable cell staining (caption A07485-1; general IHC practice).

How should I quantify PPA1 IHC across samples with different cellularity? ⚠ ANSWER MARKED FOR VERIFICATION

Define comparable viable tissue regions and score identified cell populations separately before comparing PPA1 DAB intensity (general IHC practice). For each population, report the percentage of positive cells and an H-score from 0–300, calculated from percentages at intensity grades 0–3 (general IHC practice). Normalise positive counts to the number of eligible cells, or staining density to viable tissue area in mm², and exclude necrosis and section edges consistently (general IHC practice). Record nuclear and cytoplasmic results separately because tissue IHC describes both distributions, and retain identical retrieval, development, and scoring rules across the comparison (HPA tissue IHC; general IHC practice).

Which findings argue that apparent PPA1 positivity is an artefact?

Credible staining should localise to interpretable cells and remain reproducible across matched sections; PPA1 is annotated as cytoplasmic, while tissue IHC also describes nuclear staining (UniProt Q15181; HPA tissue IHC; general IHC practice). Treat abrupt edge staining, necrotic deposits, or colour in a no-primary control as reasons to investigate section artefact or endogenous enzyme activity (general IHC practice). A pattern confined to an unexpected compartment or cell population needs corroboration, although nuclear staining alone does not contradict the reported tissue profile (HPA tissue IHC; general IHC practice). Compare the suspect area with documented high-staining glandular cells and low-staining cardiomyocytes where appropriate, using the same pH 6 retrieval and detection controls (HPA tissue IHC; datasheet A07485-1).

Boster reagents

Best PPA1 / Inorganic pyrophosphatase IHC Antibodies

Real IHC images show PPA1 staining in paraffin sections of human intestinal, lung and mammary cancers and mouse brain (catalog image captions). IF/ICC images are absent (catalog).

Real IHC data

Anti-Pyrophosphatase 1/PPA1 Antibody ®

Cat # A07485-1

View product →

A07485-1 has IHC images from paraffin sections of human intestinal, lung and mammary cancers and mouse brain (catalog image captions). Its listed applications include IHC, and its listed reactivity is human, mouse and rat; no IF/ICC validation is supplied (catalog applications and reactivity; catalog image captions).

Which to pick: Choose A07485-1 for paraffin-section chromogenic IHC: its human intestinal cancer image used citrate retrieval at pH 6 for 20 minutes and 1 μg/ml primary antibody (A07485-1 IHC image caption). The caption does not report the fixative, and the catalog lists neither IF/ICC validation nor a clone, so there is no supported IF/ICC pick (A07485-1 IHC image caption; catalog applications and clone). For cross-species IHC, A07485-1 lists human, mouse and rat reactivity, with paraffin-section images for human and mouse only (catalog reactivity; A07485-1 IHC image captions).

Each figure is that product's own IHC / IF validation image from its datasheet.

References

UniProt Consortium. UniProt entry Q15181 (IPYR_HUMAN, Inorganic pyrophosphatase).
Human Protein Atlas. PPA1 tissue IHC expression (reliability: Supported).
Human Protein Atlas. PPA1 subcellular location (ICC-IF): Localized to vesicles..
Human Protein Atlas. PPA1 antibody validation summary (2 antibodies).
Clinical significance and functional validation of PPA1 in various tumors. Cancer medicine 2016 — PMC5083733.
PPA1 promotes NSCLC progression via a JNK- and TP53-dependent manner. Oncogenesis 2019 — PMC6760234.
Mass spectrometry-based proteomic profiling of human tauopathy brains suggests mitochondria-associated alterations. Frontiers in molecular neuroscience 2026 — PMC13236917.
Proteomic profiling identifies the inorganic pyrophosphatase (PPA1) protein as a potential biomarker of metastasis in laryngeal squamous cell carcinoma. Amino acids 2016 — PMC4875942.
PubMed PMID:10542310 — UniProt-cited evidence.
PubMed PMID:10931946 — UniProt-cited evidence.
PubMed PMID:15164054 — UniProt-cited evidence.